NICE has recommended a new treatment option for those adults managing obesity and non-diabetic hyperglycaemia alongside a reduced-calorie diet and increased physical activity.
Liraglutide (also known as Saxenda) will be offered to adults with non-diabetic hyperglycaemia who have a body mass index (BMI) of at least 35 kg per m2 and have a high risk of cardiovascular disease because of risk factors such as high blood pressure or high cholesterol levels.